CATX - AMEX
Perspective Therapeutics, Inc.
$3.60
-1.1%Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
At a Glance
Live SnapshotPerspective Therapeutics, Inc. Management Team
Mr. Jonathan R. Hunt
Chief Accounting Officer
Compensation
$611,165
Mr. Amos Hedt BA, PGradDip
Chief Business Strategy Officer
Mr. Johan M. Spoor
Chief Executive Officer & Director
Compensation
$948,223
Mr. Joel David Sendek
Chief Financial Officer
Dr. Markus Puhlmann M.B.A., M.D.
Chief Medical Officer
Compensation
$702,243
Dr. Michael K. Schultz Ph.D.
Chief Science Officer
Mr. Andrew Bright
Executive Vice President of Brachytherapy
Mr. Shane Cobb
Executive Vice President of Operations
Mr. Chris Nenno
General Counsel & Corporate Secretary
Ms. Annie J. Cheng
Vice President of Investor Relations
Perspective Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $42K worth of CATX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
20.5K
42.24K
0
0.00
+42K
+$42K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Hunt Jonathan Robert
Officer: Chief Accounting Officer
$22K
Williamson Robert F Iii
Director
$20K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $42K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CATX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | April 15, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 16, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | April 18, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | August 22, 2023 | October 06, 2023 | 2023 | |
DEF 14A DEF 14A 2021 N/A | October 25, 2021 | December 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 27, 2020 | December 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 25, 2019 | December 10, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | November 09, 2018 | December 18, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | November 03, 2017 | December 14, 2017 | 2017 | |
DEF 14A DEF 14A 2017 N/A | May 17, 2017 | June 15, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.